Back to Search
Start Over
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
- Source :
-
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Feb; Vol. 22 (2), pp. 222-230. Date of Electronic Publication: 2019 Nov 14. - Publication Year :
- 2020
-
Abstract
- Aims: To investigate predictors of the initial response of beta-hydroxybutyrate (BHB) and maximum BHB (max-BHB) values during long-term therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin (TOFO), and to explore the association of the initial elevation of BHB with subsequent clinical effects in people with type 2 diabetes mellitus.<br />Methods: We analysed 774 people receiving TOFO in phase 3 trials in two groups based on measurable BHB change at week 4 (initial response): the top quartile [n = 194] and the three lower quartiles [n = 579]. Multivariate analysis was used to determine baseline predictors of inclusion in the top quartile and the max-BHB values. To investigate the association of the initial response with subsequent clinical effects, adjusted changes in variables in the two groups were compared using an analysis of covariance model.<br />Results: Of the participants, 66% were men, and the mean age, glycated haemoglobin, body mass index and estimated glomerular filtration rate were 58.5 years, 8.1%, 25.6 kg/m <superscript>2</superscript> and 83.9 mL/min/1.73 m <superscript>2</superscript> , respectively. Median changes in BHB at week 4 in the top quartile and lower three quartiles were +246.4* and +30.8* μmol/L, respectively (*P < .001 vs baseline). Lower baseline insulin secretion capacity predicted the inclusion in the top quartile and greater max-BHB levels. The top quartile was associated with greater weight loss following greater increases in free fatty acids and greater reductions in fasting C-peptide levels compared with the lower three quartiles.<br />Conclusions: Lower basal insulin secretion capacity might predict greater initial BHB elevations and max-BHB levels during long-term TOFO therapy. Greater weight loss through lipid use might be related to high initial BHB elevations.<br /> (© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
- Subjects :
- 3-Hydroxybutyric Acid metabolism
Aged
Basal Metabolism drug effects
Diabetes Mellitus, Type 2 blood
Diabetes Mellitus, Type 2 diagnosis
Diabetes Mellitus, Type 2 metabolism
Female
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Treatment Outcome
3-Hydroxybutyric Acid blood
Benzhydryl Compounds therapeutic use
Diabetes Mellitus, Type 2 drug therapy
Glucosides therapeutic use
Insulin Secretion drug effects
Weight Loss drug effects
Weight Loss physiology
Subjects
Details
- Language :
- English
- ISSN :
- 1463-1326
- Volume :
- 22
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Diabetes, obesity & metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 31608549
- Full Text :
- https://doi.org/10.1111/dom.13890